Bioavailability evaluation of innovative new formulations for the treatment of breast cancer

最近的研究强调了雷洛昔芬、来曲唑和大麻二酚（CBD）等药物在预防和/或治疗乳腺癌方面的潜力。然而，像绝大多数潜在的新化合物一样，低水溶性和口服生物利用度阻碍了有效配方的临床开发。幸运的是，使用透明质酸等药物递送剂可以克服这些限制。透明质酸是一种有趣的物质，因为它是一种天然存在于大多数组织和体液中的大多糖。一方面，它在生理和病理事件中起着重要的作用，另一方面，它也被广泛用作药物载体。因此，透明质酸与雷洛昔芬、来曲唑、CBD等药物联合使用可改善其药代动力学特性，提高其口服生物利用度。本项目的主要目标是确定雷洛昔芬和来曲唑的新分子复合物与HA单独或与CBD联合的药代动力学特性，以评估其在开发新的乳腺癌治疗方法中的潜力。动物将接受口服透明质酸制剂，并将血浆浓度与裸药进行比较。

Recent studies have highlighted the potential of dugs such as Raloxifene, Letrozole and cannabidiol (CBD) in the prevention and/or treatment of breast cancer. However, like the vast majority of potential new compounds, low aqueous solubility and oral bioavailability hinder the clinical development of effective formulations. Fortunately, such limitations could be overcome using drug delivery agents like hyaluronic acid. HA is an interesting agent as it is a macropolysaccharide naturally present in most tissues and body fluids. On the one hand, it plays important functions in physiologic and pathologic events and on the other it has also been extensively used as a drug carrier. Thus, the combination of HA with drugs like Raloxifene, Letrozole and CBD could lead to an improvement in their pharmacokinetic properties and enhanced their oral bioavailability. The main goal of this project is to determine the pharmacokinetic properties of new molecular complex of Raloxifene and Letrozole with HA alone or in combination with CBD to evaluate their potential in the development of new treatments for breast cancer. Animals will received an oral administration of the HA formulations and plasmatic concentrations will be compared to the naked drug.